NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Fennec Pharmaceuticals Inc. FENC
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$44.6M
▼ 6.1% vs FY2024
EPS · FY25
$-0.34
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-65.8%
Net margin · FY25
-21.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 44.6M
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 22 cents on every revenue dollar this year.
Per share
USD -0.34
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-65.8%
Return on equity, FY2025
ROE
Operating margin-14.1%
Net margin-21.8%
Return on assets-16.9%
Each USD of equity lost 66 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+204.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+207.5%
+204.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+31.4%
Change, 10 years+212.3%
The share count grew 31% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 70.6M
total assets, end of FY2025
Total assetsUSD 70.6M
EquityUSD 35.5M
CashUSD 36.8M
Current ratio6.37×
Equity funds 50% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
0.0
0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.34
−0.02
−0.60
−0.90
−0.67
−0.76
−0.64
−0.52
−0.47
−0.22
−0.06
−0.22
0.17
−0.21
0.19
−0.49
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−65.8
·
·
−359.2
−77.4
−88.5
−77.0
−41.1
−46.5
−135.5
−113.5
·
·
·
·
·
−174.2
−158.1
−94.4
Shares out B
0.03
0.03
0.03
0.03
0.03
0.03
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.03
0.00
0.02
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
50 of 50
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed